Welcome to our dedicated page for Misonix news (Ticker: MSON), a resource for investors and traders seeking the latest updates and insights on Misonix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Misonix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Misonix's position in the market.
Misonix, Inc. (MSON) reported strong fiscal 2021 results, achieving a fourth-quarter revenue of $19.7 million, a 43.5% increase year-over-year, and a full-year revenue of $74.0 million, up 18.5%. The gross profit margin improved to 71.5% for Q4 and 71.1% for the full year. Despite a narrowed net loss of $4.5 million in Q4 and $14.5 million for the year, the company is set to merge with Bioventus for approximately $518 million, providing shareholders with a 25% premium on stock. The merger is expected to close in late 2021.
Misonix announced the execution of a definitive merger agreement with Bioventus valued at $518 million, combining cash and stock options. Preliminary unaudited fiscal 2021 results showed a 43.5% year-over-year increase in fourth-quarter revenue to $19.7 million, with surgical revenue up 97% and wound revenue up 7.9%. For the full year, total revenue rose 18.5% to a record $74 million. Misonix shareholders will own approximately 25% of the merged entity, enjoying immediate and long-term value through this transaction.
Misonix, Inc. (Nasdaq: MSON) has appointed Patrick J. Beyer as an independent member of its Board of Directors, effective May 12, 2021. Beyer brings extensive experience, having led significant operations at ConMed and Stryker Corporation. His expertise in strategy, finance, and business development is expected to bolster Misonix's goals for sustainable growth and enhance shareholder value. Beyer expressed enthusiasm for contributing to Misonix's strategic objectives and leveraging the company's innovative ultrasonic technology to expand market share.
Misonix, Inc. (NASDAQ: MSON) announced that CEO Stavros Vizirgianakis and CFO Joe Dwyer will participate in upcoming virtual investor conferences in May and June 2021. Key events include the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, UBS Global Healthcare Conference on May 25, and the 18th Annual Craig-Hallum Institutional Investor Conference on June 2. A live webcast of the UBS event will be accessible on Misonix's website. Investors can schedule one-on-one meetings with management, with further details available through the investor relations contact.
Misonix, Inc. (MSON) reported a 2.5% revenue increase to $18.3 million for Q3 FY2021. The gross profit margin improved to 70.6%, with domestic surgical revenue rising by 14.7%. Despite a net loss of $3.8 million, loss per diluted share narrowed to $0.22 from $0.34 year-over-year. Misonix has raised its neXus Ultrasonic Surgical System placement guidance from 180 to 200 units by year-end 2021. The company anticipates full-year revenue of $72.8 million to $73.3 million, signaling a positive outlook and recovery from the pandemic's impact.
Misonix, Inc. (NASDAQ: MSON) announced it will report its fiscal 2021 third-quarter financial results on May 6, 2021, after market close. A conference call and webcast to discuss the results will follow at 4:30 p.m. ET, open to the public. Interested participants can join via phone or listen to the webcast on Misonix's website. Misonix is known for its innovative ultrasonic medical devices and regenerative products aimed at improving clinical outcomes.
Misonix has expanded its SonicOne® Ultrasonic Wound Debridement franchise by adding the Sequel line of external fixation products to its portfolio. This strategic move aims to enhance the company’s offerings in the orthoplastics market. CEO Stavros Vizirgianakis highlighted the initiative's potential to increase average revenue per procedure and improve patient outcomes. The company has also partnered with the renowned Ilizarov Center for advanced training in orthoplastic procedures. Misonix continues to focus on innovative solutions for managing complex soft tissue defects and limb salvage.
Misonix, a provider of ultrasonic medical devices, has received a Health Canada license for its neXus Ultrasonic Surgical System. This approval allows Misonix to commercialize neXus and its products in Canada, confirming compliance with Health Canada requirements. CEO Stavros Vizirgianakis expressed confidence in neXus's acceptance in Canada, similar to its success in the U.S. following a soft launch. The system is designed for multiple surgical applications and enhances treatment efficacy. Misonix aims to expand its market presence as neXus is also registered in the EU and other countries.
Misonix, Inc. (NASDAQ: MSON) will participate in the Cowen 41st Annual Healthcare Conference on March 4, 2021, at 9:50 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 4:30 p.m. ET. CEO Stavros Vizirgianakis and CFO Joe Dwyer will host one-on-one investor meetings at these events. Misonix specializes in minimally invasive ultrasonic medical devices and regenerative products for enhanced clinical outcomes.
On February 11, 2021, Misonix (NASDAQ: MSON) announced CEO Stavros Vizirgianakis and CFO Joe Dwyer will participate in two investor conferences. The BTIG Virtual MedTech Conference is scheduled for February 17-18, with Misonix presenting on February 17 at 2:00 p.m. EST. The 10th Annual SVB Leerink Global Healthcare Conference will take place on February 24-26, featuring a fireside chat on February 26 at 8:00 a.m. EST. Investors can arrange one-on-one meetings through conference representatives or contact Misonix's investor relations for more details.
